Cargando…
CD45RB Is a Novel Molecular Therapeutic Target to Inhibit Aβ Peptide-Induced Microglial MAPK Activation
BACKGROUND: Microglial activation, characterized by p38 MAPK or p44/42 MAPK pathway signal transduction, occurs in Alzheimer's disease (AD). Our previous studies demonstrated CD45, a membrane-bound protein tyrosine phosphatase (PTP), opposed β-amyloid (Aβ) peptide-induced microglial activation...
Autores principales: | Zhu, Yuyan, Hou, Huayan, Nikolic, William V., Ehrhart, Jared, Rrapo, Elona, Bickford, Paula, Giunta, Brian, Tan, Jun |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2366070/ https://www.ncbi.nlm.nih.gov/pubmed/18478117 http://dx.doi.org/10.1371/journal.pone.0002135 |
Ejemplares similares
-
Apigenin and luteolin modulate microglial activation via inhibition of STAT1-induced CD40 expression
por: Rezai-Zadeh, Kavon, et al.
Publicado: (2008) -
Inflammaging as a prodrome to Alzheimer's disease
por: Giunta, Brian, et al.
Publicado: (2008) -
Mutant presenilin-1 deregulated peripheral immunity exacerbates Alzheimer-like pathology
por: Zhu, Yuyan, et al.
Publicado: (2011) -
Stimulation of cannabinoid receptor 2 (CB(2)) suppresses microglial activation
por: Ehrhart, Jared, et al.
Publicado: (2005) -
Flipping the switches: CD40 and CD45 modulation of microglial activation states in HIV associated dementia (HAD)
por: Salemi, Jon, et al.
Publicado: (2011)